Ligand Pharmaceuticals Inc（LGND）の財務LGNDLigand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated (LGND) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Filspari, accounting for 21.9% of total sales, equivalent to $11.32M. Other significant revenue streams include Captisol and Kyprolis. Understanding this composition is critical for investors evaluating how LGND navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Ligand Pharmaceuticals Incorporated maintains a gross margin of 82.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.49%, while the net margin is 76.16%. These profitability ratios, combined with a Return on Equity (ROE) of 21.96%, provide a clear picture of how effectively LGND converts its operational activities into shareholder value.

In the context of the broader market, LGND competes directly with industry leaders such as AMRX and DFTX. With a market capitalization of $5.59B, it holds a significant position in the sector. When comparing efficiency, LGND's gross margin of 82.24% stands against AMRX's 42.01% and DFTX's N/A. Such benchmarking helps identify whether Ligand Pharmaceuticals Incorporated is trading at a premium or discount relative to its financial performance.

Ligand Pharmaceuticals has shown significant revenue growth, with Q2 revenue reaching $63.7 million, a 33.8% increase year-over-year. The company also reported a strong gross margin of 82.24% in Q2 2026, indicating efficient cost management and profitability.